Human Oncology & Pathogenesis Program
The Adrienne Boire Lab
Research
My laboratory focuses on metastasis to the central nervous system (CNS), both leptomeningeal and parenchymal metastases. We employ multiple complementary approaches to identify and target cancer cell adaptations to the challenging microenvironmental constraints posed by the CNS.
Featured News
Publications Highlights
Wijetunga NA, Goglia AG, Weinhold N, Berger MF, Cislo M, Higginson DS, Chabot K, Osman AM, Schaff L, Pentsova E, Miller AM, Powell SN, Boire A, and JT Yang 2022 Dynamic Mutational Landscape of CSF Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases. Clin Cancer Res Nov 30;CCR-22-2434.
Umemura Y, Khan B, Weill BJ, Buthorn JJ, Skakodub A, Ridder AJ, Nevel KS, Sun Y, and A Boire 2022 Discordance between perceptions and experience of lumbar puncture: A prospective study. Neurol Clin Pract 12(5):344-351.
Yang JT, Wijetunga NA, Pentsova E, Wolden S, Young RJ, Correa D, Zhang Z, Zheng J, Steckler A, Bucwinska W, Bernstein A, Betof Warner A, Yu H, Kris MG, Seidman AD, Wilcox JA, Malani R, Lin A, DeAngelis LM, Lee NY, Powell SN and A Boire 2022 Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis. J Clin Oncol 40(33):3858-3867.
Remsik J, Chi Y, Tong X, Sener U, Derderian C, Park A, Saadeh F, Bale T and A Boire 2022 Leptomeningeal metastatic cells adopt two phenotypic states. Cancer Rep (Hoboken) 5(4):e1236.
Haddock S, Alban TJ, Turcan Ş, Husic H, Rosiek E, Ma X, Wang Y, Bale T, Desrichard A, Makarov V, Monette S, Wu W, Gardner R, Manova K, Boire A, Chan TA. 2022 Phenotypic and molecular states of IDH1 mutation-induced CD24-positive glioma stem-like cells. Neoplasia 28:100790.
People
Adrienne A. Boire, MD, PhD
ScientifDirector, Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center
- Physician-scientist Adrienne Boire studies metastasis to the central nervous system.
- PhD, Tufts University, Boston, MA
- MD, University of Chicago, Chicago, IL
- 646-888-3861
- Office Phone
- View physician profile
- Physician profile
Members
- BS, Pennsylvania State University
- Cancer Biology
Lab Alumni
Lab Affiliations
Achievements
- 2021 Geoffrey Beene Junior Faculty Chair
- American Academy of Neurology Neuro Oncology Investigator Award (2020)
- Pershing Square Sohn Prize (2019)
- Pew Biomedical Scholar (2018)
- Damon Runyon Clinical Investigator Award (2017)
Open Positions
To learn more about available postdoctoral opportunities, please visit our Career Center
To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs
General Opportunities
Get in Touch
-
Office Phone
-
Office Fax
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Adrienne A. Boire discloses the following relationships and financial interests:
-
Apellis Pharmaceuticals
Professional Services and Activities -
Department of Defense/Congressionally Directed Medical Research Programs (CDMRP)
Professional Services and Activities (Uncompensated)
-
Society for Neuro-Oncology (SNO)
Professional Services and Activities
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].